This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Our new retail holding Fifth & Pacific is a high performer

By Jane Edmondson

EQM Capital's Mid Cap Quant portfolio performed in line with the benchmark S&P 400 Mid-Cap index (MID) in November. One of the top-performing names in the portfolio was apparel and accessory designer and marketer, Fifth & Pacific Companies (FNP) which was purchased for the portfolio early in November.

Fifth & Pacific operates in four segments: Juicy Couture, Lucky Brand, Kate Spade and Adelington Design Group. Shares have been rising on strong fundamentals and the prospect of the company selling its Lucky Brand denim business.

Another top performer in the portfolio was biopharma company Alkermes (ALKS). The company's product portfolio has been strengthened by its recent purchase of Elan Corporation's drug technology unit, resulting in boosted revenues. The company's legacy product Vivitrol, to treat alcohol and drug dependence, is also experiencing robust sales.

Salix Pharmaceuticals (SLXP) was another top-performing name during the month. The company develops and sells gastrointestinal drugs. Shares rose in November on an announced agreement to acquire another biotech name in the space, Santaurus (SNTS). The combined company is expected to deliver strong growth and product synergies.

One disappointing name in the portfolio was technology name InfoBlox (BLOX), which reported strong quarterly results, beating estimates by .03, but gave cautious future guidance. InfoBlox markets network control solutions. The stock hit a three-month low after reporting earnings and is currently under review as a possible candidate for sale.

Heading into the end of the year, the market will be focused on retail sales as an indicator of the health of the consumer and the overall economy. Traditionally smaller cap names have outperformed in December, which bodes well for Mid Cap stocks in my opinion.

DISCLAIMER: The investments discussed are held in client accounts as of November 30, 2013. These investments may or may not be currently held in client accounts. The reader should not assume that any investments identified were or will be profitable or that any investment recommendations or investment decisions we make in the future will be profitable. Past performance is no guarantee of future results.

 

Jane Edmondson

Jane Edmondson

I am Jane Edmondson, Founder of EQM Capital, a San Diego-based registered investment advisory firm that uses a data-driven approach

null

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs